MRA is powering a revolution in melanoma research. A revolution that is not only benefiting patients with melanoma but also impacting the field of oncology at large. MRA’s investment and power as a convener have paved the way for research advancements, scientific collaborations, and breakthroughs that are improving health outcomes every day for melanoma patients. Read our 2019 - 2020 report.
Inch by inch, year by year, and breakthrough by breakthrough, the melanoma field has made unprecedented progress that has transformed the way melanoma is diagnosed and treated. For many patients this progress is rewriting the book about what it means to face melanoma. However, there is still more to do. Read our 2018 - 2019 report.
The Melanoma Research Alliance has become the largest non-profit funder focused on melanoma. In addition to funding the best research possible, MRA also works to connect the dots between researchers, specialties, patients and families, and other stakeholders. Read our 2017 - 2018 report.
Through powerful research, the Melanoma Research Alliance (MRA) is quickly delivering results and saving lives. Over the past 10 years, MRA has invested $100 million - and leveraged an additional $90 million - to support 233 different research projects in 15 countries.
Featured in this report are some of our key achievements from the past year. These accomplishments highlight our capacity to partner with stakeholders and fund scientific studies that will accelerate transformative advances in melanoma research.
This report marks another groundbreaking year of progress for patients with melanoma. The approvals of new therapies, whether alone or
in combination with others, underscore the tremendous advancements in treatment option.
The 2013-2014 Progress Report highlights the year's incredible achievements and advancements made on behalf of melanoma patients and our continued strategy to build upon innovative developments in the field.
The 2012-2013 Snapshot of Progress reflects on the organization's accomplishments and the impact of MRA-funded programs during this pivotal time in melanoma research.